AI decision support reduces stroke patients' subsequent vascular events

The GOLDEN BRIDGE II trial in China showed a 25.6% reduction in subsequent vascular events for acute ischemic stroke patients using an artificial intelligence decision support system. The trial included 21,603 patients at 77 hospitals. The AI system improved prescription rates for dual antiplatelet therapy, statins, and anticoagulation. The intervention also led to a 29% reduction in recurrent ischemic stroke. The study was presented at the American Stroke Association's International Stroke Conference.